Multivariate predictors of MACEs during ibrutinib use
| Variable . | HR . | 95% CI . | P . |
|---|---|---|---|
| New/worsened HTN vs no/stable HTN* | 2.17 | (1.08-4.38) | .03 |
| Age ≥ 60 | 1.78 | (1.06-2.99) | .03 |
| BMI ≥30 | 1.30 | (0.84-2.02) | .24 |
| Male | 1.80 | (1.05-3.09) | .03 |
| Prior AF | 0.72 | (0.24-2.21) | .57 |
| Prior CAD | 1.38 | (0.77-2.48) | .27 |
| Prior CHF | 2.71 | (1.36-5.39) | .01 |
| Prior CVE | 0.91 | (0.34-2.39) | .85 |
| Prior DM | 1.29 | (0.74-2.25) | .37 |
| Prior CKD | 1.22 | (0.75-1.99) | .43 |
| Variable . | HR . | 95% CI . | P . |
|---|---|---|---|
| New/worsened HTN vs no/stable HTN* | 2.17 | (1.08-4.38) | .03 |
| Age ≥ 60 | 1.78 | (1.06-2.99) | .03 |
| BMI ≥30 | 1.30 | (0.84-2.02) | .24 |
| Male | 1.80 | (1.05-3.09) | .03 |
| Prior AF | 0.72 | (0.24-2.21) | .57 |
| Prior CAD | 1.38 | (0.77-2.48) | .27 |
| Prior CHF | 2.71 | (1.36-5.39) | .01 |
| Prior CVE | 0.91 | (0.34-2.39) | .85 |
| Prior DM | 1.29 | (0.74-2.25) | .37 |
| Prior CKD | 1.22 | (0.75-1.99) | .43 |
n = 562. MACE includes the combined outcome of AF, CHF, CVE, myocardial infarction, ventricular fibrillation/ventricular tachycardia, and cardiovascular death during ibrutinib use. Bold P values indicate statistically significant results.
AF, atrial fibrillation; CAD, coronary artery disease; CHF, congestive heart failure; CVE, cerebrovascular event; TIA, transient ischemic attack.
Nontime-varying HTN.